Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis, +28

Nature

Hematological MalignancyLymphoid NeoplasiaImmunologyDistinct TypesPathology +6

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

Roland Schmitz, George W. Wright, Da Wei Huang, +37

New England Journal of Medicine

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

Andreas Rosenwald, George W. Wright, Karen Leroy, +35

The Journal of Experimental Medicine

Molecular DiagnosisImmunologyPathologyImmunotherapyHematological Malignancy +14

Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

Andreas Rosenwald, Ash A. Alizadeh, George F. Widhopf, +16

The Journal of Experimental Medicine

Rearranged ImmunoglobulinEngineeringMixed-phenotype Acute LeukemiaGeneticsImmunology +15

XBP1, Downstream of Blimp-1, Expands the Secretory Apparatus and Other Organelles, and Increases Protein Synthesis in Plasma Cell Differentiation

Arthur L. Shaffer, Miriam A. Shelef, Neal N. Iwakoshi, +14

Immunity

Protein SecretionSignal TransductionDevelopmental BiologySecretory ApparatusSecretory Granules +8

Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression Program

Arthur L. Shaffer, Kuo‐I Lin, Tracy C. Kuo, +8

Immunity

Protein ExpressionCell RegulationCell SignalingImmunologyCell Fate Determination +5

Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6

Alexander L. Dent, Arthur L. Shaffer, Xin Yu, +2

Science

Signal TransducersImmune RegulationImmunologyPathologyImmunologic Mechanism +18

BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle Control

Arthur L. Shaffer, Xin Yu, Yunsheng He, +3

Immunity

InflammationCytokineAutoimmune DiseaseLymphocyte DevelopmentImmune Cell Development +10

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau, +22

The Lancet Oncology

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy +4

IRF4 addiction in multiple myeloma

Arthur L. Shaffer, N. C. Tolga Emre, Laurence Lamy, +11

Nature

Hematological MalignancyIrf4 AddictionMedicineMalignant Blood DisorderHematology +4